BIVIWBioVie Inc. Warrant
0.2800USD+12.00%Mkt Cap: —P/E: —3d ago
BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States. The company develops BIV201, that i…
Industry Peers
Biotechnology$138.82BUSDP/E 31.9
$85.87BUSDP/E 20.5
$61.34BUSDP/E 39.8
$65.05BUSDP/E 39.6
$57.94BUSD
$45.95BUSDP/E 19.6
$44.89BUSD
$42.36BUSDP/E 67.2
$35.43BUSDP/E 32.6
$31.61BUSDP/E 41.2
$29.28BUSD
$27.47BUSD
$26.22BUSD
$25.91BUSDP/E 16.2
$20.86BUSDP/E 26.3
$19.26BUSDP/E 26.6
$16.61BUSDP/E 19.6
$16.51BUSDP/E 17.4
$15.93BUSD
$13.40BUSDP/E 17.0
Key Statistics
Company
Market Cap—
Enterprise Value—
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-17.54M $
Revenue/Share—
Last Price0.2800 USD
Fiscal Year End—
MR Quarter—
Employees—
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B0.21
EPS (TTM)—
EPS (Forward)—
52W Range
0.130023% of range0.7900
52W High0.7900 USD
52W Low0.1300 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-92.27%
ROA-81.36%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-19.03M $
CapEx (TTM)—
FCF Margin—
FCF Yield—
Net Debt-8.70M $
Net Debt/EBITDA0.39
Balance Sheet
Debt/Equity0.02
Current Ratio3.59
Quick Ratio2.93
Book Value/Sh1.362 USD
Cash/Share1.190 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.—
Float7.50M
Insiders—
Institutions—
Technical
SMA 50—
SMA 200—
Beta—
S&P 52W Chg18.16%
Avg Vol (30d)158.43K
Avg Vol (10d)—
Technical Indicators
RSI (14)46.4
MACD-0.0423
MACD Signal-0.0409
MACD Hist.-0.0014
BB Upper0.5096 USD
BB Middle0.3073 USD
BB Lower0.1050 USD
BB Width131.64%
ATR (14)0.1002 USD
Vol Ratio (20d)1.08x